Last reviewed · How we verify
Pandemic influenza vaccine GSK2340272A
Pandemic influenza vaccine GSK2340272A is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of pandemic influenza.
This vaccine induces an immune response against pandemic influenza.
This vaccine induces an immune response against pandemic influenza. Used for Prevention of pandemic influenza.
At a glance
| Generic name | Pandemic influenza vaccine GSK2340272A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By stimulating the body's immune system to produce antibodies and immune cells that recognize and attack pandemic influenza virus, this vaccine helps to prevent infection and reduce the severity of symptoms.
Approved indications
- Prevention of pandemic influenza
Common side effects
- Pain, redness, swelling, or itching at the injection site
Key clinical trials
- Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children (PHASE3)
- Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A) (PHASE2)
- Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children (PHASE2)
- Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children (PHASE3)
- Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old (PHASE2)
- Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) (PHASE3)
- Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A) (PHASE3)
- Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pandemic influenza vaccine GSK2340272A CI brief — competitive landscape report
- Pandemic influenza vaccine GSK2340272A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Pandemic influenza vaccine GSK2340272A
What is Pandemic influenza vaccine GSK2340272A?
How does Pandemic influenza vaccine GSK2340272A work?
What is Pandemic influenza vaccine GSK2340272A used for?
Who makes Pandemic influenza vaccine GSK2340272A?
What development phase is Pandemic influenza vaccine GSK2340272A in?
What are the side effects of Pandemic influenza vaccine GSK2340272A?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of pandemic influenza
- Compare: Pandemic influenza vaccine GSK2340272A vs similar drugs
- Pricing: Pandemic influenza vaccine GSK2340272A cost, discount & access